Hypothesis: Trimethoprim promotes wound healing, decreases lesion counts and improves quality of life of recessive dystrophic epidermolysis bullosa (RDEB) patients.
Objectives: Assess feasibility of conducting a large randomized clinical trial. Determine efficacy of trimethoprim in healing of chronic wounds, decreasing lesion counts and improving quality of life of RDEB patients.
Methods: Prospective, randomized, double-blinded, placebo-controlled, cross-over pilot study.
Results: Ten patients enrolled in the trial, 7 completed both study periods. Despite showing that all patients improved on trimethoprim and that there was a 41% difference in affected area percent change favoring trimethoprim, the cross-over analysis did not show a significant difference between the drug and placebo (p=0.08). Secondary outcome measures did not achieve statistical significance.
Limitations: Small sample size, large variation in wound size and unaccounted confounders.
Conclusions: Although patients experienced improvement while on trimethoprim, no statistical significant change was showed when compared to placebo.
| Identifer | oai:union.ndltd.org:TORONTO/oai:tspace.library.utoronto.ca:1807/17693 |
| Date | 22 September 2009 |
| Creators | Lara-Corrales, Irene |
| Contributors | Parkin, Patricia C. |
| Source Sets | University of Toronto |
| Language | en_ca |
| Detected Language | English |
| Type | Thesis |
Page generated in 0.0206 seconds